Literature DB >> 16132906

Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients.

Ulrike Bacher1, Wolfgang Kern, Susanne Schnittger, Wolfgang Hiddemann, Claudia Schoch, Torsten Haferlach.   

Abstract

In routine diagnostic procedures of acute myeloid leukemia (AML), the French-American-British (FAB) and World Health Organization (WHO) classifications both play a central role. Some morphologic subtypes are specifically associated to distinct cytogenetic and molecular aberrations; however, such close correlations do not exist for the majority of entities. We evaluated cytogenetics in 2,235 patients at diagnosis of AML with the FAB subtypes M0-2, M4, and M5-7. The cytogenetic patterns of these subtypes showed differences with respect to the clonal aberration rate and the incidence of complex aberrant karyotypes. The frequency of numerical gains and losses and of structural losses and the incidence of 11q23/MLL rearrangements differed. Thus, cytomorphology of AML may be helpful to support or even initiate other diagnostic procedures, e.g., interphase fluorescence in situ hybridization and polymerase chain reaction. In conclusion, the central role of morphology as defined by the FAB and WHO classification in AML at diagnosis is still justified in combination with other techniques.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16132906     DOI: 10.1007/s00277-005-1099-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  12 in total

1.  Tumorigenesis in Down's syndrome: big lessons from a small chromosome.

Authors:  Dean Nižetić; Jürgen Groet
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

2.  Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia.

Authors:  Julie A Ross; Cindy K Blair; James R Cerhan; John T Soler; Betsy A Hirsch; Michelle A Roesler; Rodney R Higgins; Phuong L Nguyen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-06-29       Impact factor: 4.254

3.  HOXA9 has the hallmarks of a biological switch with implications in blood cancers.

Authors:  Laure Talarmain; Matthew A Clarke; David Shorthouse; Lilia Cabrera-Cosme; David G Kent; Jasmin Fisher; Benjamin A Hall
Journal:  Nat Commun       Date:  2022-10-03       Impact factor: 17.694

4.  Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation.

Authors:  Jessica R B Musselman; Cindy K Blair; James R Cerhan; Phuong Nguyen; Betsy Hirsch; Julie A Ross
Journal:  Cancer Epidemiol       Date:  2013-05-02       Impact factor: 2.984

5.  Spectra of chromosomal aberrations in 325 leukemia patients and implications for the development of new molecular detection systems.

Authors:  Hyun-Jung Choi; Hye-Ran Kim; Myung-Geun Shin; Hoon Kook; Hyeoung-Joon Kim; Jong-Hee Shin; Soon-Pal Suh; Dong-Wook Ryang
Journal:  J Korean Med Sci       Date:  2011-06-20       Impact factor: 2.153

6.  Distribution and features of hematological malignancies in Eastern Morocco: a retrospective multicenter study over 5 years.

Authors:  Mounia Elidrissi Errahhali; Manal Elidrissi Errahhali; Redouane Boulouiz; Meryem Ouarzane; Mohammed Bellaoui
Journal:  BMC Cancer       Date:  2016-02-25       Impact factor: 4.430

7.  Characterization of Common Chromosomal Translocations and Their Frequencies in Acute Myeloid Leukemia Patients of Northwest Iran.

Authors:  Elnaz Amanollahi Kamaneh; Karim Shams Asenjan; Aliakbar Movassaghpour Akbari; Parvin Akbarzadeh Laleh; Hadi Chavoshi; Jamal Eivazi Ziaei; Alireza Nikanfar; Iraj Asvadi Kermani; Ali Esfahani
Journal:  Cell J       Date:  2016-04-04       Impact factor: 2.479

8.  Acute leukemia in adult Hispanic Americans: a large-population study.

Authors:  R Swords; J Sznol; R Elias; J Watts; A Zelent; E Martin; F Vargas; S Bethel-Ellison; E Kobetz
Journal:  Blood Cancer J       Date:  2016-10-14       Impact factor: 11.037

9.  EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia.

Authors:  Xiuli Wang; Haiping Dai; Qian Wang; Qinrong Wang; Yang Xu; Ying Wang; Aining Sun; Jia Ruan; Suning Chen; Depei Wu
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

10.  The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias.

Authors:  Joanna Zabkiewicz; Marie Gilmour; Robert Hills; Pares Vyas; Elizabeth Bone; Alan Davidson; Alan Burnett; Steven Knapper
Journal:  Oncotarget       Date:  2016-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.